Study of SST-0225 Topical Ibuprofen Cream in the Treatment of Delayed Onset Muscle Soreness (DOMS)
Status:
Completed
Trial end date:
2016-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, prospective, randomized, dual-center, double-blind, placebo-controlled,
parallel-group study designed to determine the efficacy and safety of SST-0225 (5.4 grams,
applied up to 6 times in 24 hours, over a 48-hour dosing period) for the treatment of pain
associated with DOMS.